2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy

CARDIOMYOPATHY1. Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all testing and treatment options, discussion of the risks and benefits of those options and, importantly, engagement of the patient to express their own goals, is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy (HCM).2. Although the primary cardiology team can initiate evaluation, treatment, and longitudinal care, referral to multidisciplinary HCM centers with graduated levels of expertise can be important to optimizing care for patients with HCM.Challenging treatment decisions-where